FDA-Catalyst COPD, Asthma, And Respiratory Disease Effectiveness (CARE) For 21st Century Cures: Feasibility Assessments for Comparative Effectiveness Studies

Project Title FDA-Catalyst COPD, Asthma, And Respiratory Disease Effectiveness (CARE) For 21st Century Cures: Feasibility Assessments for Comparative Effectiveness Studies
Date Posted
Tuesday, November 6, 2018
Status
In progress
Description

The main goal of this activity is to leverage existing Sentinel data and tools to perform feasibility assessments for subsequent chronic obstructive pulmonary disease (COPD) and asthma comparative effectiveness studies.  The workgroup will conduct descriptive analyses that will include exploration of cohort definitions, medication utilization, and effectiveness outcomes, and will also attempt to replicate selected standard definitions for COPD and asthma cohorts.

Workgroup Leader(s)

Judith C. Maro PhD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

David Martin MD, MPH; Center for Drug Evaluation and Research, Office of the Center Director, FDA, Silver Spring, MD

Workgroup Members

Catherine A. Panozzo PhD, Elnara Fazio-Eynullayeva MA, David Cole BM, Catherine Rogers Murray MPH; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

Population / Cohort
Individuals with COPD and asthma
Data Sources
Sentinel Distributed Database (SDD)